Dr. Suresh K. Durgam M.D. Net Worth

The estimated Net Worth of Suresh K. Durgam is at least $5.51 Million dollars as of 7 March 2024. Dr Durgam owns over 10,162 units of Intra-Cellular Therapies Inc stock worth over $1,479,680 and over the last 4 years he sold ITCI stock worth over $3,302,822. In addition, he makes $730,360 as Sr. VP & Chief Medical Officer at Intra-Cellular Therapies Inc.

Dr D ITCI stock SEC Form 4 insiders trading

Dr has made over 17 trades of the Intra-Cellular Therapies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 10,162 units of ITCI stock worth $672,826 on 7 March 2024.

The largest trade he's ever made was exercising 62,282 units of Intra-Cellular Therapies Inc stock on 2 January 2024 worth over $1,237,543. On average, Dr trades about 10,067 units every 55 days since 2021. As of 7 March 2024 he still owns at least 19,803 units of Intra-Cellular Therapies Inc stock.

You can see the complete history of Dr Durgam stock trades at the bottom of the page.

Dr. Suresh K. Durgam M.D. biography

Dr. Suresh K. Durgam M.D. is the Sr. VP & Chief Medical Officer at Intra-Cellular Therapies Inc.

What is the salary of Dr D?

As the Sr. VP & Chief Medical Officer of Intra-Cellular Therapies Inc, the total compensation of Dr D at Intra-Cellular Therapies Inc is $730,360. There are 9 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.

How old is Dr D?

Dr D is 52, he's been the Sr. VP & Chief Medical Officer of Intra-Cellular Therapies Inc since . There are 13 older and 3 younger executives at Intra-Cellular Therapies Inc. The oldest executive at Intra-Cellular Therapies Inc is Richard Lerner, 81, who is the Independent Director.

What's Dr D's mailing address?

Suresh's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.

Insiders trading at Intra-Cellular Therapies Inc

Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus und Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.

What does Intra-Cellular Therapies Inc do?

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Complete history of Dr Durgam stock trades at Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc executives and stock owners

Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:

• Sharon Mates,
  Chairman of the Board, President, Chief Executive Officer
• Mark Neumann,
  Executive Vice President, Chief Commercial Officer
• Michael Halstead,
  Executive Vice President, General Counsel and Secretary
• Lawrence Hineline,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
• Robert Davis,
  Senior Vice President and Chief Scientific Officer
• Kimberly Vanover,
  Senior Vice President, Early Stage Clinical Development and Translational Medicines
• Dr. Sharon Mates,
  Co-Founder, Chairman, CEO & Pres
• Mark Neumann,
  EVP & Chief Commercial Officer
• Michael I. Halstead J.D.,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Suresh K. Durgam M.D.,
  Sr. VP & Chief Medical Officer
• Lawrence J. Hineline CPA, CPA,
  Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
• Robert Van Nostrand,
  Lead Independent Director
• Joel Marcus,
  Independent Director
• Christopher Alafi,
  Independent Director
• Rory Riggs,
  Independent Director
• Richard Lerner,
  Independent Director
• Michael Olchaskey,
  Senior Vice President, Head of Regulatory Affairs
• Suresh Durgam,
  Chief Medical Officer
• John Bardi,
  Senior Vice President - Market Access, Policy and Government Affairs
• Karen Patruno Sheehy Esq.,
  Sr. VP & Chief Compliance Officer
• Juan Fernando Sanchez,
  VP of Corp. Communications & Investor Relations
• Dr. Robert E. Davis Ph.D.,
  Sr. VP & Chief Scientific Officer
• Moshe Alafi,
  10% owner
• Capital Co Llc Alafi,
  10% owner
• Juan F. Sanchez,
  VP, Corp. Communications & IR
• Allen A. Fienberg,
  VP of Business Development
• Lawrence P. Wennogle,
  Vice President, Drug Discovery
• Michael Rawlins,
  Director
• Eduardo Rene Salas,
  
• Sanjeev Narula,
  Executive Vice President & CFO